21 – 30 of 55
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab : Results from the Phase II PROMIX trial
(
- Contribution to journal › Article
-
Mark
Germline mutations in BRCA1 and BRCA2 incidentally revealed in a biobank research study : experiences from re-contacting mutation carriers and relatives
(
- Contribution to journal › Article
-
Mark
Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial
(
- Contribution to journal › Article
- 2017
-
Mark
Abstract P1-07-17: The SCAN-B study: 5-year summary of a large-scale population-based prospective breast cancer translational genomics platform covering a wide geography of Sweden (NCT02306096)
(
- Contribution to journal › Published meeting abstract
-
Mark
Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer
(
- Contribution to journal › Article
- 2016
-
Mark
Transcriptional profiling of breast cancer metastases identifies liver metastasis-selective genes associated with adverse outcome in luminal A primary breast cancer.
(
- Contribution to journal › Article
-
Mark
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
(
- Contribution to journal › Article
-
Mark
Is Breast-conserving Therapy Really a Good Option for BRCA1/2 Mutation Carriers?
(
- Contribution to journal › Article
-
Mark
The state of the art in prediction of breast cancer relapse using cell-free circulating tumor DNA liquid biopsies
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic
(
- Contribution to journal › Article